On May 28, 2024 Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, reported that members of the executive management team will participate in a presentation at the 44th Annual William Blair Growth Stock Conference on Tuesday, June 4 at 2:00 p.m. (CT) (Press release, LabCorp, MAY 28, 2024, View Source [SID1234643737]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On May 28, 2024 ISA reported that Dr Caroline Even, oncologist at Institut Gustave Roussy, will present the results of the double blind OpcemISA clinical trial with 199 patients at the ASCO (Free ASCO Whitepaper) annual conference (Press release, ISA Pharmaceuticals, MAY 28, 2024, View Source [SID1234643736]). The study evaluates the addition of the Human Papilloma Virus type 16 (HPV16) directed cancer vaccine ISA101b to an anti-PD-1 checkpoint inhibitor (CPI) in patients with recurrent metastatic HPV16 induced head and neck cancers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This trial is the first to have generated randomized, placebo-controlled data of the contribution of a cancer vaccine in this indication. The results of this study offer unique biomarker-defined insights as regards patient selection, thereby substantially derisking future clinical development of ISA101b.

Patients with 1st or 2nd line recurrent and/or metastatic HPV16 positive oropharyngeal cancer (OPC) were treated with CPI plus ISA101b or placebo until disease progression or withdrawal. Further information about the study design can be found on clinicaltrials.gov (NCT03669718).

Presentation Title: Results of a randomized, double-blind, placebo-controlled, phase 2 study (OpcemISA) of the combination of ISA101b and cemiplimab versus cemiplimab for recurrent/metastatic (R/M) HPV16-positive oropharyngeal cancer (OPC)
Presentation Time: Tuesday June 4th, 2024, 09:45 CDT
Presenting Author: Dr. Caroline Even, Principal Investigator
Session (oral): Head and Neck Cancer
Abstract #: 6003
Head-and-neck cancer is one of the most aggressive and life-threatening malignancies. HPV16 is fast becoming the predominant cause of head-and-neck cancer. Recurrent and metastatic HPV16 positive OPC is a form of head-and-neck cancer with a high unmet medical need that may be susceptible to this form of combined immunotherapy. In September 2021 ISA101b was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of recurrent and metastatic HPV16 positive OPC.

For more information, please contact us at [email protected].

On May 28, 2024 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") reported members of its executive team are scheduled to participate in the upcoming conferences, detailed below (Press release, Innate Pharma, MAY 28, 2024, View Source [SID1234643735]). Participants will include Hervé Brailly, Chief Executive Officer, Sonia Quaratino, Executive Vice President (EVP), Chief Medical Officer, Yannis Morel, EVP, Chief Operating Officer and Arvind Sood, EVP, President of US Operations.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies Global Healthcare Conference
Event dates: June 5-6, 2024 | New York, United States

Goldman Sachs 45th Annual Global Healthcare Conference
Event dates: June 10-13, 2024 | Miami, United States

H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
Event date: June 25, 2024 | Virtual

Stifel 2nd European Healthcare Summit Lyon
Event dates: June 25-27, 2024 | Lyon, France

On May 28, 2024 Exelixis, Inc. (Nasdaq: EXEL) reported that company management will participate in a fireside chat at the William Blair 44th Annual Growth Stock Conference on Tuesday, June 4 at 4:20 p.m. ET / 3:20 p.m. CT / 1:20 p.m. PT in Chicago (Press release, Exelixis, MAY 28, 2024, View Source [SID1234643734]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the webcast link, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading. A replay will also be available at the same location for at least 30 days.

On May 28, 2024 Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, reported that company management will participate in the following conferences and invited investors to participate by webcast (Press release, Exact Sciences, MAY 28, 2024, View Source [SID1234643733]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

William Blair 44th Annual Growth Stock Conference, Chicago
Presentation on Tuesday, June 4, 2024 at 1:40 p.m. ET
Jefferies Healthcare Conference, New York
Fireside chat on Wednesday, June 5, 2024 at 11:00 a.m. ET
Goldman Sachs 45th Annual Global Healthcare Conference, Miami
Fireside chat on Tuesday, June 11, 2024 at 3:20 p.m. ET

The webcasts can be accessed in the investor relations section of Exact Sciences’ website at www.exactsciences.com.